Impact Events
MoreDate | Lead Company |
Event | Type | Approval Change |
Approval Likelihood |
---|---|---|---|---|---|
2/25/21 | SpringWorks Therapeutics (SWTX) | Mirdametinib for Neurofibromatosis (NF) | Subscribers Only | Subscribers Only | Subscribers Only |
2/24/21 | Johnson & Johnson (JNJ) | JNJ-78436735 for COVID-19 Prevention | Subscribers Only | Subscribers Only | Subscribers Only |
2/22/21 | Immunicum AB (IMMU) | Ilixadencel for Renal Cell Cancer (RCC) | Subscribers Only | Subscribers Only | Subscribers Only |
2/22/21 | Otonomy (OTIC) | Otividex for Meniere's Disease | Subscribers Only | Subscribers Only | Subscribers Only |
2/22/21 | AbbVie (ABBV) | Rinvoq for Ulcerative Colitis (UC) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range |
Lead Company |
Drug | Expected Catalyst |
---|---|---|---|
08/16/19 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
02/26/21 | Subscribers Only | Subscribers Only | Regulatory - PDUFA/Approval Decision (US) |
02/26/21 | Subscribers Only | Subscribers Only | Regulatory - PDUFA/Approval Decision (US) |
Now - 02/27/21 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
02/27/21 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |